United States - English - NLM (National Library of Medicine)

douglas pads & sports, inc - isopropyl alcohol (unii: nd2m416302) (isopropyl alcohol - unii:nd2m416302) - antiseptic health care personnel hand rub to help reduce bacteria that potentially can cause disease.

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - fexofenadine hydrochloride 120mg; fexofenadine hydrochloride 120mg - film coated tablet - 120 mg - active: fexofenadine hydrochloride 120mg excipient: croscarmellose sodium hyprolose hypromellose iron oxide red iron oxide yellow macrogol 400 magnesium stearate microcrystalline cellulose opacode black s-1-8152hv povidone purified talc purified water titanium dioxide active: fexofenadine hydrochloride 120mg excipient: croscarmellose sodium hyprolose hypromellose iron oxide red iron oxide yellow macrogol 400 magnesium stearate microcrystalline cellulose opacode black s-1-27794 povidone purified talc purified water titanium dioxide

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - fexofenadine hydrochloride 180mg; fexofenadine hydrochloride 180mg - film coated tablet - 180 mg - active: fexofenadine hydrochloride 180mg excipient: croscarmellose sodium hyprolose hypromellose iron oxide red iron oxide yellow macrogol 400 magnesium stearate microcrystalline cellulose opacode black s-1-8152hv povidone purified talc purified water titanium dioxide active: fexofenadine hydrochloride 180mg excipient: croscarmellose sodium hyprolose hypromellose iron oxide red iron oxide yellow macrogol 400 magnesium stearate microcrystalline cellulose opacode black s-1-27794 povidone purified talc purified water titanium dioxide

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - pethidine hydrochloride 100mg;   - tablet - 100 mg - active: pethidine hydrochloride 100mg   excipient: lactose monohydrate magnesium stearate maize starch microcrystalline cellulose opadry white y-1r-7000b povidone purified water sodium starch glycolate

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - pethidine hydrochloride 50mg;   - tablet - 50 mg - active: pethidine hydrochloride 50mg   excipient: lactose monohydrate magnesium stearate maize starch microcrystalline cellulose opadry white y-1r-7000b povidone purified water sodium starch glycolate

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - captopril, quantity: 12.5 mg - tablet, uncoated - excipient ingredients: lactose; microcrystalline cellulose; maize starch; palmitic acid; colloidal anhydrous silica; purified talc - hypertension: captopril (captopril) is indicated for the treatment of hypertension. in using captopril, consideration should be given to the risk of neutropenia/agranulocytosis (see warnings). captopril is effective alone and in combination with other antihypertensive agents, especially thiazide-type diuretics. the blood pressure lowering effects of captopril and thiazides are approximately additive. myocardial infarction: captopril (captopril) is indicated to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction, manifested as an ejection fraction less than or equal to 40%, and to reduce the incidence of overt heart failure and subsequent hospitalisations for congestive heart failure in these patients. the efficacy data for the use of captopril following myocardial infarction are strongest for initiation of therapy beyond three days post-infarction. heart failure: captopril (captopril) is indicated for the treatment of heart failure. in symptomatic patients it is recommended that captopril be administered together with a diuretic. diabetic nephropathy: captopril (captopril) is indicated for the treatment of diabetic nephropathy in patients with type i insulin-dependent diabetes mellitus.

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - captopril, quantity: 25 mg - tablet, uncoated - excipient ingredients: lactose; microcrystalline cellulose; maize starch; palmitic acid; colloidal anhydrous silica; purified talc - hypertension: captopril (captopril) is indicated for the treatment of hypertension. in using captopril, consideration should be given to the risk of neutropenia/agranulocytosis (see warnings). captopril is effective alone and in combination with other antihypertensive agents, especially thiazide-type diuretics. the blood pressure lowering effects of captopril and thiazides are approximately additive. myocardial infarction: captopril (captopril) is indicated to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction, manifested as an ejection fraction less than or equal to 40%, and to reduce the incidence of overt heart failure and subsequent hospitalisations for congestive heart failure in these patients. the efficacy data for the use of captopril following myocardial infarction are strongest for initiation of therapy beyond three days post-infarction. heart failure: captopril (captopril) is indicated for the treatment of heart failure. in symptomatic patients it is recommended that captopril be administered together with a diuretic. diabetic nephropathy: captopril (captopril) is indicated for the treatment of diabetic nephropathy in patients with type i insulin-dependent diabetes mellitus.

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - captopril, quantity: 50 mg - tablet, uncoated - excipient ingredients: lactose; microcrystalline cellulose; maize starch; palmitic acid; colloidal anhydrous silica; purified talc - hypertension: captopril (captopril) is indicated for the treatment of hypertension. in using captopril, consideration should be given to the risk of neutropenia/agranulocytosis (see warnings). captopril is effective alone and in combination with other antihypertensive agents, especially thiazide-type diuretics. the blood pressure lowering effects of captopril and thiazides are approximately additive. myocardial infarction: captopril (captopril) is indicated to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction, manifested as an ejection fraction less than or equal to 40%, and to reduce the incidence of overt heart failure and subsequent hospitalisations for congestive heart failure in these patients. the efficacy data for the use of captopril following myocardial infarction are strongest for initiation of therapy beyond three days post-infarction. heart failure: captopril (captopril) is indicated for the treatment of heart failure. in symptomatic patients it is recommended that captopril be administered together with a diuretic. diabetic nephrophathy: captopril (captopril) is indicated for the treatment of diabetic nephropathy in patients with type i insulin-dependent diabetes mellitus.

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - piperacillin sodium (equivalent: piperacillin, qty 4000 mg) - injection, powder for - excipient ingredients: - piperacillin sodium is indicated for treatment of systemic and local infections due to susceptible gram-negative and gram-positive aerobic and anaerobic bacteria. its efficacy has also been demonstrated in infections caused by some carbenicillin resistant organisms. appropriate cultures should be made before initiating treatment. therapy may be started while awaiting results of susceptibility testing. treatment should be adjusted, if necessary, when results of testing become available. piperacillin sodium is indicated for prophylactic use in surgery including intra-abdominal (gastrointestinal and urinary tract) procedures, vaginal hysterectomy, and caesarean section. efficacy has not been demonstrated in biliary tract procedures. effective prophylaxis depends on the time of administration; piperacillin sodium should be given 1/2 to 1 hour before the operation so that effecitve levels can be achieved in the wound prior to the procedure. the exception to this rule is in caesarean section where pipercillin sodium should be administered after clamping the umbilical cord. types of infection: piperacillin sodium is recommended for the treatment of the following types of infection caused by one or more susceptible pathogens. severe systemic infections; including bacterial septicaemia, endocarditis. genitourinary tract infections (complicated and uncomplicated), including urethritis, cystitis and pyelonephritis. it is also effective in acute, uncomplicated infections caused by neisseria gonorrhoeae. respiratory tract infections ( acute and chronic), including bronchitis, pneumonia, empyema and lung abscess. in patients with chronic respiratory infections of cystic fibrosis, clinical improvement has been achieved but bacterial eradication may not occur. ear, nose, throat and oral cavity infections. intra-abdominal infections, including those of the biliary tract and intra-abdominal abscess. gynaecological and obstetric infections, including endometritis, pelvic abscess and inflammation, salpingitis and puerperal infections. skin and skin structure infections, including those following infected wounds and burns, surgery and trauma. bone and joint infections. piperacillin sodium should be used at reduced dosage in adults with severely restricted kidney function (see dosage and administration). combined therapy with other antibiotics. aminoglycosides. based on in-vitro synergism and clinical results, combined therapy with piperacillin and aminoglycoside antibiotics (eg amikacin) may be used in the treatment of serious infections caused by such organisms as klebsiella, indole-positive proteus, pseudomonas and serratia. both piperacillin and the respective aminoglycoside should be given at the full therapeutic dose. cephalosporins. if piperacillin sodium is proposed to be administered concomitantly with a cephalosporin, an additive, synergistic or antagonistic antibacterial action of the two antibiotics should first be ascertained through in-virtro tests. based on in-vitro data, cefoxitin should not be given with piperacillin. piperacillin sodium has not been shown to be physically compatible with cephalosporins when mixed in the same infusion fluid. note: whenever piperacillin sodium is administered concurrently with another antibiotic, they should not be mixed in the same solution but must be administered separately.

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - piperacillin sodium (equivalent: piperacillin, qty 2000 mg) - injection, powder for - excipient ingredients: - piperacillin sodium is indicated for the treatment of systemic and local infections due to susceptible gram-negative and gram-positive aerobic and anaerobic bacteria. its efficacy has also been demonstrated in infections caused by some carbenicillin resistant organisms. appropriate cultures should be made before initiating treatment. therapy may be started while awaiting results of susceptibility testing. treatment should be adjusted, if necessary, when results of testing become available. piperacillin sodium is indicated for prophylactic use in surgery including intra-abdominal (gastrointestinal and urinary tract) procedures, vaginal hysterectomy, and caesarean section. efficacy has not been demonstrated in biliary tract procedures. effective prophylaxis depends on the time of administration; piperacillin sodium should be given 1/2 to 1 hour before the operation so that effective levels can be achieved in the wound prior to the procedure. the exception to this rule is in caesarean section where piperacillin sodium should be administered after clamping the umbilical cord. types of infection: piperacillin sodium is recommended for the treatment of the following types of infection caused by one or more susceptible pathogens. severe systemic infections, including bacterial septicaemia, endocarditis. genitourinary tract infections (complicated and uncomplicated), including urethritis, cystitis and pyelonephritis. it is also effective in acute, uncomplicated infections caused by neisseria gonorrhoeae. respiratory tract infections (acute and chronic), including bronchitis, pneumonia, empyema and lung abscess. in patients with chronic respiratory infections or cystic fibrosis, clinical improvement has been achieved but bacterial eradication may not occur. ear, nose, throat and oral cavity infections. intra-abdominal infections, including those of the biliary tract and intra-abdominal abscess. gynaecological and obstetric infections, including endometritis, pelvic abscess and inflammation, salpingitis and puerperal infections. skin and skin structure infections, including those following infected wounds and burns, surgery and trauma. bone and joint infections. piperacillin sodium should be used at reduced dosage in adults with severely restricted kidney function (see dosage and administration). combined therapy with other antibiotics. aminoglycosides. based on in-vitro synergism and clinical results, combined therapy with piperacillin and aminoglycoside antibiotics (eg amikacin) may be used in the treatment of serious infections caused by such organisms as klebsiella, indole-positive proteus, pseudomonas and serratia. both piperacillin and the respective aminoglycoside should be given at the full therapeutic dose. cephalosporins. if piperacillin sodium is proposed to be administered concomitantly with a cephalosporin, and additive, synergisitc or antagonistic antibacterial action of the two antibiotics should first be ascertained through in-vitro tests. based on in-vitro data, cefoxitin should not be given with piperacillin. piperacillin sodium has not been shown to be physically compatible with cephalosporins when mixed in the same infusion fluid. note: whenever piperacillin sodium is administered concurrently with another antibiotic, they should not be mixed in the same solution but must be administered separately.